Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Fineline Cube Jan 29, 2026
Company Deals

WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases

Fineline Cube Jan 29, 2026
Company Deals

NeuShen Therapeutics Raises Series A+ for CNS Drug Development

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026
Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026
Company Deals

CNBG and Sinopharm Form Partnership to Integrate Medical Industries

Fineline Cube Apr 4, 2023

China National Biotec Group Company Ltd (CNBG) has announced a strategic partnership with its parent...

Company Deals

Beijing’s Surgerii Secures Series C3 Financing to Advance Endoscopic Surgical Robot Technology

Fineline Cube Apr 4, 2023

Beijing-based endoscopic surgical robot developer, Beijing Surgerii Robotics Company Limited, has reportedly raised hundreds of...

Company Drug

Lynk Pharmaceuticals Concludes Phase I Study for JAK Inhibitor LNK01003 with Positive Results

Fineline Cube Apr 4, 2023

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd has announced the successful conclusion of a Phase I...

Company Deals

BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets

Fineline Cube Apr 4, 2023

Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that...

R&D

China’s Life Expectancy on Track to Surpass 81.3 Years by 2035, Study Reveals

Fineline Cube Apr 3, 2023

A recent study published in The Lancet has provided updated forecasts for life expectancy in...

Company Deals

Willingmed Secures Series B Funding to Advance Clinical Infection Diagnostics

Fineline Cube Apr 3, 2023

Willingmed, a Beijing-based company specializing in molecular biology for clinical infection precision diagnosis, has reportedly...

Policy / Regulatory

CDE Launches Guidelines to Expedite Pediatric and Rare Disease Drug Reviews

Fineline Cube Apr 3, 2023

The Center for Drug Evaluation (CDE) has unveiled a new set of “Work Specifications to...

Company Drug

Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma

Fineline Cube Apr 3, 2023

China’s Center for Drug Evaluation (CDE) has indicated that US pharmaceutical giant Johnson & Johnson’s...

Company Drug

CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer

Fineline Cube Apr 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study

Fineline Cube Apr 3, 2023

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced receiving approval...

Company Drug

Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Prolia

Fineline Cube Apr 3, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving market approval from the...

Company Drug

Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment

Fineline Cube Apr 3, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study

Fineline Cube Apr 3, 2023

China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National...

Company Drug

Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC

Fineline Cube Apr 3, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results...

Company Deals

Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation

Fineline Cube Apr 3, 2023

The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...

Company Drug

Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis

Fineline Cube Apr 3, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...

Company Drug

Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012

Fineline Cube Apr 3, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...

Company

Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization

Fineline Cube Apr 3, 2023

China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...

Company

Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates

Fineline Cube Mar 31, 2023

China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...

Company Deals Digital

ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector

Fineline Cube Mar 31, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has...

Posts pagination

1 … 492 493 494 … 616

Recent updates

  • United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial
  • Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China
  • Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform
  • Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered
  • WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.